Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS)

• ClinicalTrials.gov Identifier: NCT01786603
• Recruitment Status: Completed
• First Posted: February 8, 2013
• Results First Posted: January 27, 2020
• Last Update Posted: January 27, 2020
• Sponsor: Richard Barohn, MD
• Information provided by (Responsible Party): Richard Barohn, MD, University of Kansas Medical Center

Study Description

Brief Summary:

ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. Motor neurons are responsible for sending signals to muscles in our bodies to trigger movement. While there are drugs to help relieve symptoms of ALS, there is no cure for ALS.

Rasagiline is a drug with possible neuroprotective characteristics. Neuroprotective means that the nervous system may be protected against weakening. It is known that rasagiline has possible neuroprotective characteristics, but the effectiveness of rasagiline for patients with ALS has not been tested. Rasagiline is approved for the treatment of Parkinson's disease.

Rasagiline for treatment of ALS is not approved by the U.S. Food and Drug Administration (FDA) and is investigational. Investigational drugs are studied to find out if they are safe and effective in the treatment of diseases or conditions.

By doing this study, researchers hope to learn if rasagiline is safe and slows disease progression in patients with ALS.

Funding Source - FDA OOPD (FDA Orphan Products Division).

Condition or disease	Intervention/treatment	Phase
Amyotrophic Lateral Sclerosis (ALS)	Drug: Rasagiline; Drug: Placebo	Phase 2

Detailed Description:

The study is a phase II, double-blind, placebo-controlled, multicenter study of rasagiline 2mg/day. Subjects will be assigned to either active agent or placebo (3:1) for twelve months. Subjects will undergo outpatient evaluations at screening, baseline, and months 1, 2, 4, 6, 8, 10 and 12 and telephone assessments at months 3, 5, 7 and 9. There will be a close-out phone call 30 days post month 12.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 80 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Care Provider, Investigator)
• Primary Purpose: Treatment
• Official Title: Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis
• Actual Study Start Date: November 21, 2013
• Actual Primary Completion Date: July 27, 2016
• Actual Study Completion Date: July 27, 2016

Arms and Interventions

Arm	Intervention/treatment
Experimental: Rasagiline; Rasagiline 1mg administered orally as a 2mg single dose once daily for 12 months.	Drug: Rasagiline; Rasagiline 2mg once a day for 12 months.; Other Name: Azilect
Placebo Comparator: Placebo; Inactive ingredient equal to 1mg rasagiline 2mg administered as a single dose once daily for 12 months.	Drug: Placebo; Placebo (looks like study drug but has no active ingredients) once a day for 12 months.

Outcome Measures

Primary Outcome Measures :

1. ALS Functional Rating Scale-Revised (ALSFRS-R) [ Time Frame: ALS Functional Rating Scale-Revised (ALSFRS-R) Difference from Baseline to Month 12 ]
   Difference in ALS Functional Rating Scale - Revised (ALSFRS-R) score. The ALSFRS-R is an ordinal rating scale that assesses 12 functional activities. Each activity is scored between 0-4, with a total score ranging from 48 (normal function) to 0 (no function).

Secondary Outcome Measures :

1. Change in Vital Capacity (VC) [ Time Frame: Vital Capacity Change from Baseline to Month 12 ]
   Determine if decline in vital capacity is slower in participants taking 2 mg rasagiline than controls.
2. Change in Quality of Life [ Time Frame: Quality of Life Change from Baseline to Month 12 ]
   Participants completed the single-item ALSQOL (ALS Quality of Life) which asks participants to rank their global quality of life, considering all parts of their lives - physical, emotional, social, spiritual and financial - in the last 7 days and rate on a scale of 0 (very bad) to 10 (excellent).
3. Number of Participants With Adverse Events [ Time Frame: Adverse Events from Baseline to Month 12 ]
   Determine if participants on rasagiline 2 mg had a different safety profile than patients not on rasagiline. Adverse event information to be collected from date of enrollment until end of study participation.
4. Difference in Survival Status Between Study Groups [ Time Frame: Survival status at Month 12 ]
   Determine if there is a difference in survival between participants on rasagiline than patients not on rasagiline
5. Effect of Study Drug on Apoptosis Markers [ Time Frame: Apoptosis Marker change from Baseline to Month 12 ]
   Effect of rasagiline on the apoptosis markers (Annexin V stain) in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.
6. Effect of Study Drug on Oxidative Stress [ Time Frame: Oxidative Stress change from Baseline to Month 12 ]
   Determine if oxygen radical antioxidant capacity is targeted by rasagiline in participants with ALS. Assessed at baseline, month 6, and month 12; change from baseline to month 12 reported. Extra time point was not a pre-specified Primary or Secondary Outcome Measure.

Eligibility Criteria

• Ages Eligible for Study: 21 Years to 80 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. A clinical diagnosis of laboratory-supported probable, probable, or definite ALS, according to a modified El Escorial criteria, by the study investigator (Appendix IV).
2. 21 to 80 years of age inclusive.
3. VC greater or equal to 75% of predicted at screening and baseline.
4. Onset of weakness within 2 years prior to enrollment.
5. If patients are taking riluzole for ALS, they must be on a stable dose for at least thirty days prior to the baseline visit.
6. Women of childbearing age must be non-lactating and surgically sterile or using an effective method of birth control and have a negative pregnancy test.
7. Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).

Exclusion criteria

1. Requirement for tracheotomy ventilation or non-invasive ventilation for > 23 hours per day.
2. Patients on sympathomimetic agents. This includes pseudoephedrine, phenylephrine, phenylpropanolamine, and ephedrine.
3. Patients on analgesics with serotoninergic properties such as meperidine, tramadol, methadone and propoxyphene, flexeril.
4. Patients on fluoxetine or fluvoxamine.
5. Patients taking amitriptyline > 50 mg/d, trazodone and sertraline > 100 mg/d, citalopram > 20 mg/d or paroxetine > 30 mg/d.
6. Diagnosis of other neurodegenerative diseases (Parkinson disease, Alzheimer disease, etc).
7. Clinically significant history of unstable medical illness (unstable angina, advanced cancer, etc) over the last 30 days.
8. Has a diaphragm pacing device or plan on obtaining a diaphragm pacing device during the course of the study.
9. History of renal disease.
10. History of liver disease.
11. Current pregnancy or lactation.
12. Limited mental capacity such that the patient cannot provide written informed consent or comply with evaluation procedures.
13. History of recent alcohol or drug abuse or noncompliance with treatment or other experimental protocols.
14. Vital Capacity (VC) < 75% of predicted.
15. Receipt of any investigational drug within the past 30 days.
16. Women with the potential to become pregnant who are not practicing effective birth control.
17. Poorly controlled hypertensive subjects or resting systolic blood pressure (SBP) > 160 mmHg and/or diastolic (DBP) > 95 mmHg.
18. Use of BiPAP at screening.

Contacts and Locations

Locations

United States, Arizona

Phoenix Neurological Associates

Phoenix, Arizona, United States, 85018

United States, California

University of California - Irvine

Irvine, California, United States, 92868

California Pacific Medical Center

San Francisco, California, United States, 94115

United States, Kansas

University of Kansas Medical Center

Kansas City, Kansas, United States, 66160

United States, Missouri

St. Louis University

Saint Louis, Missouri, United States, 63104

United States, Nebraska

University of Nebraska

Omaha, Nebraska, United States, 68198

United States, New York

Columbia University

New York, New York, United States, 10032

United States, Oregon

Oregon Health and Science University

Portland, Oregon, United States, 97239

United States, Pennsylvania

University of Pennsylvania

Philadelphia, Pennsylvania, United States, 19107

United States, Texas

UT Southwestern Medical Center

Dallas, Texas, United States, 75390

Sponsors and Collaborators

Richard Barohn, MD

Investigators

• Principal Investigator: Richard Barohn, MD; University of Kansas Medical Center

More Information

• Responsible Party: Richard Barohn, MD, Gertrude and Dewey Zeigler Professor of Neurology and Chair, University of Kansas Medical Center
• ClinicalTrials.gov Identifier: NCT01786603
• Other Study ID Numbers: 12312; R01FD003739 ( U.S. FDA Grant/Contract )
• First Posted: February 8, 2013
• Results First Posted: January 27, 2020
• Last Update Posted: January 27, 2020
• Last Verified: January 2020

Additional relevant MeSH terms:

Motor Neuron Disease; Amyotrophic Lateral Sclerosis; Sclerosis; Pathologic Processes; Neurodegenerative Diseases; Nervous System Diseases; Neuromuscular Diseases; Spinal Cord Diseases; Central Nervous System Diseases; TDP-43 Proteinopathies; Proteostasis Deficiencies; Metabolic Diseases; Rasagiline; Monoamine Oxidase Inhibitors; Enzyme Inhibitors; Molecular Mechanisms of Pharmacological Action; Neuroprotective Agents; Protective Agents; Physiological Effects of Drugs